ZLD — Zelira Therapeutics Cashflow Statement
0.000.00%
- AU$3.97m
- AU$10.66m
- AU$0.10m
Annual cashflow statement for Zelira Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | -3.51 | -1.63 | -1.09 | -0.757 | -0.941 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -6.94 | -8.62 | -9.43 | -7.25 | -4.39 |
Capital Expenditures | -0.016 | 0 | — | — | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 1.12 | 1.38 | -0.208 | 2.83 | 0.92 |
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 1.11 | 1.38 | -0.208 | 2.83 | 0.92 |
Financing Cash Flow Items | -0.287 | -0.088 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 4.5 | 10.5 | 7.1 | 1.77 | 3.92 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1.38 | 3.27 | -2.22 | -2.6 | 0.44 |